Summary
Merck & Co., Inc. (MRK) reported strong financial results for the quarter ended June 30, 2022. Net sales increased significantly year-over-year, driven by robust performance across key franchises, particularly in Oncology (Keytruda) and Vaccines (Gardasil/Gardasil 9). The company also saw substantial contributions from its antiviral medication Lagevrio. Despite increased costs, especially related to the collaboration with Ridgeback for Lagevrio, Merck maintained healthy profitability. The company's strategic investments in research and development and business development initiatives, including collaborations in July 2022 for ODM-208 and MK-1200, position it for future growth. Merck also reiterated its full-year 2022 sales guidance for Lagevrio, expecting between $5.0 billion and $5.5 billion.
Financial Highlights
53 data points| Revenue | $14.59B |
| Cost of Revenue | $4.22B |
| Gross Profit | $10.38B |
| R&D Expenses | $2.80B |
| SG&A Expenses | $2.51B |
| Operating Income | $8.25B |
| Interest Expense | $240.00M |
| Net Income | $3.94B |
| EPS (Basic) | $1.56 |
| EPS (Diluted) | $1.55 |
| Shares Outstanding (Basic) | 2.53B |
| Shares Outstanding (Diluted) | 2.54B |
Key Highlights
- 1Merck reported a substantial increase in net sales, up 28% year-over-year to $14.6 billion for the quarter, driven by strong product demand and contributions from Lagevrio.
- 2Keytruda sales continued their upward trajectory, growing 26% to $5.3 billion, supported by new indications and strong global uptake.
- 3The Vaccines segment showed robust growth, with Gardasil/Gardasil 9 sales up 36% to $1.7 billion, indicating strong demand for HPV vaccines.
- 4Lagevrio, an antiviral COVID-19 medicine, generated $1.2 billion in sales for the quarter, contributing significantly to the company's top-line growth.
- 5Research and Development expenses decreased by 35% year-over-year, primarily due to a large acquisition-related charge in the prior year, while strategic investments in new collaborations continue.
- 6The company continues to actively manage its pipeline with new collaborations announced in July 2022 for ODM-208 (oncology) and MK-1200 (oncology), indicating a focus on innovation.
- 7Merck maintained a strong liquidity position with $10.4 billion in cash and investments at quarter-end and generated $9.1 billion in operating cash flow for the first six months of 2022.